Lipid therapy

• US 8,785,382 B2
• Filed: 03/30/2007
• Issued: 07/22/2014
• Est. Priority Date: 04/03/2006
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Kilpatrick, Deborah, Hossainy, Syed Faiyaz Ahmed, Astafieva, Irina, Ludwig, Florian N., Consigny, Paul M., Ellis, Jeffrey T., Lim, Florencia
• Primary Examiner(s): KIM, ALEXANDER D
• Application Number:
  US11/694,793
• Publication Number:
  US 20070232539A1
• Time in Patent Office: 2,671 Days
• Field of Search: None
• US Class Current: 514/7.4
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1275 Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1658 Proteins, e.g. albumin, gelatin
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61M 2202/0456 Lipoprotein
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method including introducing into a blood stream a delipidated high density lipoprotein (HDL) and a bioactive agent. A composition including a delipidated high density lipoprotein (HDL) and an auxiliary agent in a form suitable for delivery into a blood vessel. A composition including Apo A1 comprising a hydrophobic ligand suitable to interact with cell surface binding sites. A composition including Apo A1 and an agent selected to one of increase the ATP-binding cassette protein 1 (ABCA1) transporter expression in macrophages and protect ABCA1 from thiol-mediated degradation.

Claims

1. A method for treating a subject comprising:

withdrawing an amount of blood from the subject using a catheter assembly;

delipidating high density lipoprotein (HDL) present in the amount of blood, wherein delipidating comprises combining the amount of blood with a solvent and a surfactant;

adding a surface coating to the delipidated HDL for increasing a partition coefficient of the delipidated HDL; and

after delipidating, (1) combining an exogenous bioactive agent having a hydrophobic ligand bound thereto with the delipidated HDL with the surface coating, wherein the exogenous bioactive agent includes at least one of an apolipoprotein A1 (Apo A1), a functional Apo A1 mutant, and a functional Apo A1 mimetic peptide, and (2) forming a composition comprising (i) the delipidated HDL with the surface coating combined with the exogenous bioactive agent having a hydrophobic ligand bound thereto, and (ii) a viscosifier including at least one of hyaluronic acid, polyvinylpyrrolidone (PVP), a hydroxypropylmethacrylate (HPMA) copolymer system, and carboxymethyl cellulose (CMC); and

introducing the composition into a blood stream or tissue of the subject, using the catheter assembly.

2. The method of claim 1, wherein introducing comprises systemically introducing.

3. The method of claim 1, wherein introducing comprises locally introducing.

4. The method of claim 1, wherein introducing comprises locally introducing to an ischemic area.

5. The method of claim 1, wherein introducing comprises introducing the delipidated HDL upstream from a treatment site.

6. The method of claim 1, wherein introducing comprises introducing to a periadventitial area.

7. The method of claim 6, further comprising introducing a gel-forming biomaterial to the periadventitial area.

8. The method of claim 1, wherein withdrawing, delipidating and introducing comprise a closed loop system.

9. The method of claim 1, wherein the hydrophobic ligand is selected from the group consisting of an elastin pentapeptide, leucine-rich oligopeptide, stearoyl, olyeol and palmitoyl.

10. The method of claim 1 wherein the surfactant is selected from the group consisting of a sulfate, a sulfonate, a phosphate, a carboxylate and a sulfosuccinate.

11. A method for treating a subject comprising:

delivering to a treatment site within a lumen of a blood vessel of the subject, in a wall of the blood vessel of the subject, or periadvential area beyond the blood vessel by a percutaneous transluminal route, a composition comprising (i) a delipidated HDL and an exogenous bioactive agent having a hydrophobic ligand bound thereto, the delipidated HDL comprising an added surface coating having a property that increases a partition coefficient of the delipidated HDL into the treatment site, and (ii) a viscosifier,

wherein the delivering step comprises locally delivering by placing a stent within the blood vessel of the subject, wherein the stent comprises the composition as a coating on a body of the stent or as a portion of the body of the stent, and

wherein the viscosifier comprises at least one of hyaluronic acid, polyvinylpyrrolidone (PVP), a hydroxypropylmethacrylate (HPMA) copolymer system, and carboxymethyl cellulose (CMC), and

wherein the exogenous bioactive agent includes at least one of an apolipoprotein A1 (Apo A1), a functional Apo A1 mutant, and a functional Apo A1 mimetic peptide.

12. The method of claim 11, wherein prior to delivering the agent, the method comprises:

occluding the blood vessel at a point upstream of a treatment site and a point downstream of the treatment site.

13. The method of claim 11, wherein prior to delivering the delipidated HDL, the method further comprises at least partially occluding the blood vessel at a treatment site with a porous occlusion device, and delivering comprises delivering the agent through the porous occlusion device.

14. The method of claim 11, wherein prior to delivering the agent, the method comprises inserting an occlusion device into the blood vessel that at least partially occludes the blood vessel, and delivering comprises delivering the agent through the occlusion device.

15. The method of claim 14, wherein the occlusion device comprises a balloon assembly comprising a porous portion and delivering comprises delivering the one of the agent through the porous portion.

16. The method of claim 14, wherein the occlusion device comprises a sponge.

17. The method of claim 11, wherein the treatment site comprises a periadventitial area.

18. The method of claim 17, further comprising introducing a gel biomaterial to the periadvential area.